SemaThera has benefitted from the Amorchem early stage incubation model, where Amorchem’s own development specialists partner with an academic research laboratory in order to bring the technology to a proof of concept before either investing further funds or licensing the early stage asset to an industrial partner. In the case of SemaThera, this process led to Amorchem making a $1 million seed investment as founding investor.
They were joined at that point by development partner Senju Pharmaceutical Co., Ltd. From Osaka, Japan. Senju Pharmaceutical Co., Ltd. develops pharmaceutical products for eye, ear, nose, throat, and skin care. It offers prescription drugs in various categories, such as inflammation, allergy, glaucoma, cataract, infection, surgical aid, and cornea protection. The company also offers over-the-counter products. It serves customers in Asia, North and South America, Europe, and the Middle East. Senju Pharmaceutical Co., Ltd. was founded in 1947 and is based in Osaka, Japan.